U.S. Markets closed

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.540+0.03 (+1.99%)
At close: 3:59PM EDT
People also watch

MannKind Corporation

25134 Rye Canyon Loop
Suite 300
Valencia, CA 91355
United States

Full Time Employees153

Key Executives

Dr. Michael E. Castagna Pharm.D.Chief Exec. Officer, Chief Commercial Officer & Director378.41kN/A40
Dr. David B. Thomson Ph.D., J.D.Corp. VP, Gen. Counsel and Corp. Sec.458.68k424.8k50
Dr. Raymond W. Urbanski M.D., Ph.D.Chief Medical Officer and Corp. VP501.32kN/A58
Ms. Rosabel Realica AlinayaActing Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin.N/AN/A56
Mr. Joseph KocinskyChief Technology Officer and Corp. VP of Technical OperationsN/AN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Valencia, California.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of June 2, 2017 is 5. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.